SEOUL, SOUTH KOREA--() September 06, 2012 -- The Korea Tourism Organization has released Visit Korea 2.0, the upgraded version of the original Visit Korea smartphone application.
Visit Korea 2.0 contains expanded travel content and information on Korea's tourist attractions, restaurants, accommodations, shops, and more. All listings have a map to assist travelers in navigation. Visit Korea 2.0 features increased user-friendliness by adding such convenient functions as links to Social Networking Services.
The KTO hopes that Visit Korea 2.0 will meet the demand of the increasing number of travelers using smartphones to access information about travel in Korea.
In accordance with the launching of the Visit Korea 2.0 smartphone application, Korea Tourism Organization is holding the Visit Korea 2.0 App Review Contest on its official website, Visit Korea. The KTO also plans to hold such online events as ‘Create your own QR Code’ via Facebook and Twitter. Detailed information on the current and upcoming online events can be found on the Visit Korea website ().
Visit Korea 2.0 can be downloaded for free from the iTunes App Store and the Google Play Store for iPhones and Android Phones.
Website link for download:
iPhone Download ()
Android Download ()Korea Tourism Organization has released Visit Korea 2.0. Visit Korea 2.0 contains expanded travel content and information on Korea's tourist attractions, restaurants, accommodations, shops, and more.
INCHEON, KOREA--( / ) 하타노유이 내복남 November 23, 2015 -- Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for 콩토렌트 조루증치료약 Medicinal Products for Human Use (CHMP) has adopted a positive opinion on 호두티비TV INCHEON,하타노유이 한송이과거 - 콩토렌트 a biosimilar version of Enbrel® (etanercept), previously known as SB4 - for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) and plaque 하타노유이 열혈초등학교99 psoriasis. This marks the first time the CHMP has adopted a positive opinion on an etanercept biosimilar.
The CHMP’s positive opinion will now be referred to 하타노유이 소아비뇨기과 the European Commission (EC) which will review and 호두티비TV Theon the grant of 하타노유이 남자찢어진청바지 a marketing authorization for Benepali®. If a marketing 하타노유이 여자야상남방 authorization is granted, Benepali® will be the first etanercept biosimilar to be approved in 콩토렌트 비뇨기과필러 the European Union (EU).
“We are very pleased to have developed the first 콩토렌트 파스 etanercept biosimilar to 하타노유이 디아제팜 receive a positive CHMP opinion,” said Christopher Hansung 자브자브 “We하타노유이 젓가락녀 CEO of Samsung Bioepis. “By leveraging our strengths in 황진이 “Wedevelopment and quality assurance, we will continue to focus 하타노유이 찌찌빠빠 on developing affordable, high-quality biologic treatment options 콩토렌트 저지 for patients in Europe who need these life-enhancing medications.”
This positive CHMP opinion on Benepali® was based on Phase 1 and Phase 3 clinical studies that tested the biosimilarity of Benepali® to Enbrel®. In the 52-week Phase 3 clinical study, which involved 하타노유이 리포푼딘 596 patients randomized across 70 sites in 10 countries, Benepali® demonstrated comparable safety and equivalent efficacy to 혼다리코 Thisas 콩토렌트 게스언더웨어파티 evidenced in ACR20 하타노유이 슈다페드 response rate of 80.8% in the Benepali® arm 하타노유이 versus 81.5% in the Enbrel® arm.
In addition to Benepali®, Samsung Bioepis has been developing two other anti-tumor necrosis 콩토렌트 연고통 factor-alpha (anti-TNF-α) investigational biosimilar candidates, 유토파일구 Inlatest clinical 하타노유이 study results for which are as follows: 콩토렌트 아이비승무원학원
· SB2 investigational biosimilar candidate to Remicade® (infliximab): On November 9, 2015 at the Annual Meeting of the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) in San Francisco, Samsung 콩토렌트 Bioepis announced 54-week SB2 clinical study results that showed comparable safety and equivalent efficacy to Remicade®, as evidenced in ACR20 response rate of 아는토렌트 ·in the SB2 arm versus 69.2% in the Remicade® arm. The SB2 study randomized 584 patients with moderate to 콩토렌트 비너스 severe rheumatoid arthritis despite methotrexate therapy across 73 sites in 11 countries. In March 2015, Samsung Bioepis submitted to the EMA a Marketing Authorization Application for SB2, for which a 하타노유이 수액세트 CHMP opinion has 콩토렌트 유아물사마귀 yet to be announced.
아는토렌트 ·하타노유이 콩토렌트
SB5 investigational biosimilar candidate to Humira® (adalimumab): On November 10, 2015 at the ACR/ARHP 아는토렌트 SB5Meeting in San Francisco, Samsung Bioepis announced 아이폰고스톱어플 SB5하타노유이 냉동수술기 Phase 3 clinical study results that showed comparable safety and equivalent efficacy to Humira®, as evidenced in 콩토렌트 ACR20 response rate of 72.5% in the SB5 하타노유이 핑클영원 arm versus 72.0% in the Humira® arm. The study randomized 544 patients with moderate to severe rheumatoid arthritis despite 하타노유이 겐타마이신 methotrexate therapy across 52 sites in seven countries.
Samsung 콩토렌트 Bioepis was established in 2012 with a 비뇨기과상담 Samsungto develop affordable, high-quality biopharmaceutical products and to provide 콩토렌트 티벳궁녀반전몸매 better patient 콩토렌트 access to life-enhancing medications. The company aims to be the world’s leading biopharmaceutical company through innovations in 하타노유이 product development and quality assurance.
Samsung 콩토렌트 에피네프린 Bioepis has commercial agreements with Biogen 바로박 SamsungMerck to commercialize and distribute biosimilar products in immunology and oncology. 레드19 Samsungproducts 하타노유이 박민영장근석 and geographic responsibilities include:
스타킹각선미 Biogen하타노유이 박민영성형 콩토렌트 박민영성형
· SB4, investigational biosimilar candidate referencing Enbrel® 하타노유이 (etanercept) 양산성인용품판매사이트 ·콩토렌트 박민영나이 European Union, Switzerland, 하타노유이 박민영성형한곳 Japan
신덕동홀덤카페 Merck하타노유이 인터넷 실시간 tv 방송 콩토렌트 인터넷 실시간 tv 방송
· 콩토렌트 강소라 올19 ·investigational biosimilar candidate referencing 하타노유이 실시간방송 어플 Remicade® (infliximab) - Worldwide, 하타노유이 지나란제리화보 including United States, but excluding European Union, 하타노유이 차분 Switzerland, Russia, Turkey
· SB5, investigational biosimilar candidate referencing Humira® javsin ·- Worldwide, including 하타노유이 콩토렌트 United States, but excluding European 콩토렌트 10대속옷쇼핑몰 Union, Switzerland, Russia, Turkey
View 콩토렌트 source version on businesswire.com:Korea Newswire distributes your news across every 블랙TV Viewchannels through the industry’s largest 하타노유이 중학생여자수영복 콩토렌트 중학생여자수영복 press 하타노유이 10대수영복추천 release distribution network
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.